Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-25
2011-01-25
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024310, C514S04400A
Reexamination Certificate
active
07875711
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.
REFERENCES:
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
Huang Ihi-Ming et al: “Activation of hepatitis B virus S promoter by a cell type-restricted IREI-dependent pathway induced by endoplasmic reticulum stress.” Molecular and Cellular Biology Sep. 2005, vol. 25, No. 17, Sep. 2005, pp. 7522-7533.
Lee Ann-Hwee et al: “Proteasome inhibitors disrupt the unfolded protein response in myeloma cells” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, US, vol. 100, No. 17, Aug. 19, 2003, pp. 9946-9951.
Romero-Ramirez Lorenzo et al: “XBPI is essential for survival under hypoxic conditions and is required for tumor growth.” Cancer Research Sep. 1, 2004, vol. 64, No. 17, Sep. 1, 2004, pp. 5943-5947.
Yu Chia-Yi et al: “Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress.” Journal of Virology Dec. 2006, vol. 80, No. 23, Dec. 2006, pp. 11868-11880.
International Search Report and Written Opinion, PCT/US2009/040962, Nov. 24, 2009, 15 Pages.
Invitation of Pay Additional Fees and, Where Applicable, Protest Fee, Communication Relating to the Results of the Partial International Search, PCT/US2009/040962, Oct. 5, 2009, 7 Pages.
Agrawal, S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate”, The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.
Elbashir, S., et al., “RNA Interference is Mediated By 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference by Double Stranded RNA inCaenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation By Double-Stranded RNA in Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Lee, A.-H., et al., “Regulation of Hepatic Lipogenesis by the Transcription Factor XBP1,” Science, Jun. 13, 2008, pp. 1492-1496, vol. 320.
Fitzgerald Kevin
Hinkle Gregory
Alnylam Pharamaceuticals, Inc.
Chong Kimberly
Fenwick & West LLP
LandOfFree
Compositions and methods for inhibiting expression of XBP-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of XBP-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of XBP-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619616